anti-TRAIL-R4 (human), mAb antibody (HS402)

Specifications / Handling

More Information
Product Details
Synonyms	TRAIL Receptor 4; TRUNDD; DcR2; TNFRSF10D; CD264
Product Type	Monoclonal Antibody
Properties
Clone	HS402
Isotype	Mouse IgG1
Source/Host	Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen	Recombinant human TRAIL-R4 (DcR2).
Application	Flow Cytometry Immunocytochemistry Immunohistochemistry: (frozen sections) Immunoprecipitation
Crossreactivity	Human
Specificity	Recognizes human TRAIL-R4. Does not cross-react with human TRAIL-R1, -R2 or -R3.
Purity	≥95% (SDS-PAGE)
Purity Detail	Protein G-affinity purified.
Concentration	1mg/ml
Formulation	Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Isotype Negative Control	Mouse IgG1 Isotype Control
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

TRAIL-R4 is a receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.

Product References

TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol. 170, 1814 (2003)
TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood 103, 517 (2004)
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ. 11 Suppl 1, S86 (2004)
cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem. 279, 52824 (2004)
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood 111, 4780 (2008)
The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2: T. Hartwig, et al.; Mol. Cell 65, 730 (2017)

Call	+41 61 926 6040
Fax	+41 61 926 6049

anti-TRAIL-R4 (human), mAb (HS402)